Newsletter Current page: 4

Dr Cornelius Maas is responsible for the so-called deal flow at SHS. One of his main tasks is to find suitable companies in which SHS would like to invest. Fundraising for the SHS VI fund is running very successfully and is almost complete. Time for a few questions for Dr Maas: Dr Maas, what criteria […]

The Swiss company TRI® Dental Implants now offers dental practices a super-fast workflow for restoring implant patients in just 60 minutes. This is made possible by the unique matrix® implant line, which requires no abutments and no cement. A real step forward for patients and dentists. More information: https://t1p.de/yqjgz

Gentoo penguins (Pygoscelis papua) live on sub-Antarctic islands and can dive more than 180 metres deep, their maximum speed in the water is around 35 km/h. Since penguins do not have gills, but are birds with lungs, researchers from the Fundación Oceanogràfic want to find out how exactly the lungs of gentoo penguins work. To […]

On the occasion of a meeting of the renowned French Académie Nationale de Chirurgie at the Institut Faire Faces, the First Lady of France, Brigitte Macron, was able to personally convince herself of the performance of the CARLO® surgical robot. The Institut Faire Faces was founded in 2009 in Amiens, the birthplace of Brigitte Macron, […]

Here we introduce you to the SHS senior advisors. The experience of these experts plays an important role for us in the investment process and benefits not least our portfolio companies. Dr Enzelberger is currently a partner at Versant Ventures in Basel, where he builds new companies in drug discovery and biotechnology. Prior to that, […]

In our series “SHS portfolio companies”, today we talk to Tobias Richter, founder and CEO of the Swiss TRI Dental Implants Int. AG, in which SHS has held a stake since 2014. In 2011, Tobias Richter founded the company TRI Dental Implants in Switzerland. The graduate economist comes from a family of doctors in East […]

The most important goals in the invasive treatment of myocardial infarction are to reduce infarct size, improve cardiac function and minimise the likelihood of permanent heart failure. To achieve these goals, Belgium-based Miracor Medical has developed the PiCSO® (Pressore Controlled Intermittent Coronary Sinus Occlusion) system. With the start of the new PICSO-AMI-V study at the […]

Tübingen, 3 November 1906: Alzheimer’s disease described for the first time 3 November 1906 is an important date in the history of Alzheimer’s disease. For on this Saturday, the physician Dr. Alois Alzheimer (14.6.1864 – 19.12.1915) described a type of dementia disease for the first time at a specialist conference at the Tübingen Nervenklinik. Alzheimer, […]

With the CARLO® surgical robot for high-precision laser cutting of bones, the Swiss medical robotics company AOT has already made technological history in the operating theatre. More than 80 procedures have already been successfully performed on patients with CARLO®. The system is CE-certified for all of Europe. Now the medical robotics experts at AOT have […]

The medical technology industry has not exactly had it easy in the last two years. In addition to the pandemic, which has shaken the industry, the MDR (Medical Device Regulation) of the EU and digitalisation in particular present companies with major challenges that tie up manpower and capital. In addition, there are now pandemic-related supply […]

Here we introduce you to the SHS senior advisors. The experience of these experts plays an important role for us in the investment process and benefits not least our portfolio companies. Professor Dr. rer. nat. Armin Bolz was Professor of Biomedical Engineering at KIT from 1999 to 2013. At the same time, he founded and […]

Founded in 2013, our portfolio company Lowenco is already one of the leading providers of ultra-low temperature solutions for the global biopharma industry after just a few years. A success that is also reflected in the company’s books. As of 31.12.2021, Lowenco reports an increase in operating profit of around 32 percent to now 80 […]